Chen Franco-Yehuda
2021
In 2021, Chen Franco-Yehuda earned a total compensation of $1.4M as Chief Financial Officer at Pluristem Therapeutics, a 550% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $64,000 |
|---|---|
| Salary | $251,642 |
| Stock Awards | $1,020,000 |
| Other | $14,653 |
| Total | $1,350,295 |
Franco-Yehuda received $1M in stock awards, accounting for 76% of the total pay in 2021.
Franco-Yehuda also received $64K in non-equity incentive plan, $251.6K in salary and $14.7K in other compensation.
Rankings
In 2021, Chen Franco-Yehuda's compensation ranked 7,669th out of 12,415 executives tracked by ExecPay. In other words, Franco-Yehuda earned more than 38.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,669 out of 12,415 | 38th |
Division Manufacturing | 3,379 out of 5,508 | 39th |
Major group Chemicals And Allied Products | 1,495 out of 2,378 | 37th |
Industry group Drugs | 1,329 out of 2,099 | 37th |
Industry Biological Products, Except Diagnostic Substances | 303 out of 449 | 33rd |
Source: SEC filing on February 27, 2023.
Franco-Yehuda's colleagues
We found two more compensation records of executives who worked with Chen Franco-Yehuda at Pluristem Therapeutics in 2021.
News
Pluristem Therapeutics CEO Yaky Yanay's 2023 pay jumps 111% to $2.7M
May 1, 2024
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020